Amgen (AMGN) Hisse Özeti
Amgen Inc. dünya çapında insan terapötiklerini keşfeder, geliştirir, üretir ve sunar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 5/6 |
AMGN Community Fair Values
Create NarrativeSee what 178 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amgen Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$358.33 |
| 52 Haftanın En Yüksek Seviyesi | US$391.29 |
| 52 Haftanın En Düşük Seviyesi | US$269.77 |
| Beta | 0.42 |
| 1 Aylık Değişim | 6.63% |
| 3 Aylık Değişim | 2.74% |
| 1 Yıllık Değişim | 29.30% |
| 3 Yıllık Değişim | 61.40% |
| 5 Yıllık Değişim | 44.08% |
| Halka arzdan bu yana değişim | 254,712.44% |
Son Haberler & Güncellemeler
Seeking Alpha • 19h
Amgen Continues To Perform
Summary Amgen is rated between Hold and Buy, with shares potentially slightly undervalued or fairly valued depending on free cash flow assumptions. Newer products like Repatha, Evenity, and Tezspire are driving double-digit growth, offsetting steep declines from legacy drugs Enbrel and Prolia. Management guides 2026 revenue of $37.1–$38.5B and non-GAAP EPS of $21.70–$23.10, reflecting steady but moderate growth. Balance sheet caution is warranted due to $57B in debt, though a robust pipeline and possible upside from MariTide support long-term optimism. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 14
AMGN: IRS Dispute And Tax Overhang Will Pressure Future Returns
Narrative Update on Amgen Analysts have adjusted Amgen's fair value estimate by about $1 to $244.55 as they balance a lower discount rate and slightly higher projected profit margins against more cautious revenue growth assumptions and recent shifts in Street price targets tied to the ramp of Uplizna and ongoing IRS dispute commentary. Analyst Commentary Recent Street research on Amgen has been mixed, with some firms raising price targets around the launch of Uplizna in generalized myasthenia gravis and others trimming targets as they factor in tax uncertainty and differing views on long term growth drivers.Recent updates
Seeking Alpha • 19h
Amgen Continues To Perform
Summary Amgen is rated between Hold and Buy, with shares potentially slightly undervalued or fairly valued depending on free cash flow assumptions. Newer products like Repatha, Evenity, and Tezspire are driving double-digit growth, offsetting steep declines from legacy drugs Enbrel and Prolia. Management guides 2026 revenue of $37.1–$38.5B and non-GAAP EPS of $21.70–$23.10, reflecting steady but moderate growth. Balance sheet caution is warranted due to $57B in debt, though a robust pipeline and possible upside from MariTide support long-term optimism. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 14
AMGN: IRS Dispute And Tax Overhang Will Pressure Future Returns
Narrative Update on Amgen Analysts have adjusted Amgen's fair value estimate by about $1 to $244.55 as they balance a lower discount rate and slightly higher projected profit margins against more cautious revenue growth assumptions and recent shifts in Street price targets tied to the ramp of Uplizna and ongoing IRS dispute commentary. Analyst Commentary Recent Street research on Amgen has been mixed, with some firms raising price targets around the launch of Uplizna in generalized myasthenia gravis and others trimming targets as they factor in tax uncertainty and differing views on long term growth drivers.
Anlatı Güncellemesi • May 31
AMGN: Fair Outlook Balances Rare Disease Potential With Expanded Manufacturing Investment
Amgen's fair value estimate has shifted modestly higher to about $352 per share, up from roughly $350. This reflects analysts' mixed price target revisions around $427 and updated expectations for rare disease and other growth drivers.Anlatı Güncellemesi • May 14
AMGN: Fair Outlook Weighs Pipeline Execution Against Expanded Manufacturing Commitments
Analysts have nudged the Amgen price target slightly lower to about $350. This reflects a modest increase in the discount rate, slightly softer revenue growth assumptions and a small reduction in the future P/E multiple, partly offset by a higher projected profit margin and a mix of recent upgrades, downgrades and price target revisions across the Street.Anlatı Güncellemesi • Apr 28
AMGN: Recent Rally And Trial Uncertainty Will Pressure Future Returns
Amgen's fair value estimate has moved from about $230.89 to $243.49 as analysts factor in a series of higher price targets from firms across the Street, balanced by several neutral initiations. These initiations point to solid fundamentals but mixed views on potential upside from this level.
Anlatı Güncellemesi • Apr 14
AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models. Analyst Commentary Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.Anlatı Güncellemesi • Mar 30
AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.Anlatı Güncellemesi • Mar 16
AMGN: Fair Outlook Balances Patent Expiries With Late Stage Pipeline Potential
The Analyst Price Target for Amgen has been updated from $327.74 to $350.03 as analysts factor in recent price target increases tied to stronger near term commercial execution, added value from key Phase 3 pipeline assets, and a shift toward discounted cash flow based models that emphasize improved margin assumptions and a slightly lower discount rate. Analyst Commentary Recent Street commentary around Amgen reflects a mix of optimism about the current execution and pipeline, alongside ongoing debate about valuation, product risks, and long term earnings durability.Anlatı Güncellemesi • Mar 02
AMGN: Obesity And Cardiovascular Pipeline Will Drive Future Cash Generation
The analyst price target for Amgen in this narrative has moved to $432. Analysts point to updated DCF assumptions, slightly lower revenue growth and profit margin inputs, and a modestly higher future P/E multiple supported by recent price target increases across the Street and ongoing confidence in the pipeline and guidance.Anlatı Güncellemesi • Feb 16
AMGN: Long Patent Expiries And Heavier Spending Will Pressure Future Earnings
Analysts have lifted their price targets on Amgen by about $12 to reflect updated views on fair value, profitability, and future P/E assumptions, while also factoring in a higher discount rate and lower projected revenue growth. Analyst Commentary Recent research on Amgen points to a split view, with several firms lifting price targets while others are turning more cautious.Analiz Makalesi • Feb 11
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.52 on 6th of...Anlatı Güncellemesi • Feb 02
AMGN: Obesity And Cardiovascular Pipeline Will Shape Long-Term Cash Generation
Analysts have nudged their Amgen price targets higher by about $10 to $20, citing a shift toward discounted cash flow analysis, steady execution in legacy products, and increased confidence in the obesity and cardiovascular pipeline. Analyst Commentary Recent research on Amgen highlights a wide range of opinions, but there is a clear cluster of bullish analysts who are leaning into higher price targets and more constructive ratings.Analiz Makalesi • Jan 21
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year
Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...Anlatı Güncellemesi • Jan 19
AMGN: Obesity And Cardiovascular Pipeline Will Support Long-Term Upside Potential
Analysts have raised their price targets on Amgen into a higher range, with moves such as BofA's shift to a discounted cash flow approach and UBS's upgraded view on earnings and pipeline potential, even as others highlight upcoming patent expiries and spending needs that temper expectations. Analyst Commentary Recent research on Amgen shows a mix of cautious and constructive views, but the price target moves cluster in a higher range, with several firms now anchoring their models around pipeline contributions and cash flow potential alongside the existing portfolio.Analiz Makalesi • Jan 07
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52...Anlatı Güncellemesi • Jan 05
AMGN: Patent Expiries And New Drug Launches Will Shape Future Performance
Analysts nudged their fair value estimate for Amgen higher to about $328 per share, up from roughly $323. This reflects slightly firmer revenue expectations and a higher assumed future P/E, balanced against more conservative profit margin assumptions and mixed Street views that highlight both the stability of the core business and uncertainty around patent expiries and new launches.Anlatı Güncellemesi • Dec 15
AMGN: Margin Expansion And Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for Amgen higher to approximately $425 from about $405, reflecting a more constructive view on the company as a defensive large cap biotech with improving margin potential and an innovation pipeline that, while still facing patent expiry and execution risks, is increasingly seen as capable of supporting long term earnings power. Analyst Commentary Recent Street research on Amgen highlights a balanced but gradually improving sentiment backdrop, with a growing cohort of bullish analysts positioning the company as a core large cap biotech holding.Anlatı Güncellemesi • Nov 30
AMGN: Future Pipeline Progress And Revenue Diversification Will Shape Performance
Amgen's analyst price target has been raised modestly to $322.88, with analysts citing stable revenue, recent guidance increases, and optimism around its pipeline despite ongoing challenges related to patent expiries. Analyst Commentary Recent Street research provides a nuanced view of Amgen’s valuation, outlook, and potential risk factors, with opinions split between those optimistic about its growth trajectory and those concerned about near-term challenges.Anlatı Güncellemesi • Nov 16
AMGN: Future Pipeline Progress And Profit Margins Will Guide Near-Term Performance
Amgen's fair value target has increased by approximately $7 to $318.51, as analysts highlight robust profit margin improvement and sustained pipeline progress in their latest updates. Analyst Commentary Recent updates from Wall Street reveal a mix of optimism and caution surrounding Amgen’s outlook.Analiz Makalesi • Aug 13
Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
Even though Amgen Inc. ( NASDAQ:AMGN ) posted strong earnings, investors appeared to be underwhelmed. We have done some...Analiz Makalesi • Aug 01
Is Amgen (NASDAQ:AMGN) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Apr 17
Amgen: The Biotech That Knows How To Make Money
Summary Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen achieved record revenues of $33.4 billion in 2024, with strong EBITDA growth and high free cash flow, despite increased debt from acquisitions. The company's balanced business model and innovative pipeline, including promising drugs in oncology and cardiometabolic diseases, support a "Buy" rating with a 16.44% growth potential. Key risks include expiring patents and regulatory pressures, but Amgen's diversified strategy and strong cash flow position it well for future growth. Read the full article on Seeking AlphaYeni Anlatı • Apr 08
Biosimilar Competition And TEPEZZA Approvals Will Define Future Path
Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.Yeni Anlatı • Apr 08
Expanding Oncology Portfolio And International Launches Will Unlock Potential
Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.Seeking Alpha • Mar 31
Amgen: Excellent Buy And Hold For A Volatile Market
Summary Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock. Read the full article on Seeking AlphaSeeking Alpha • Mar 10
Amgen: Riding The MariTide Of Monthly Weight Loss
Summary Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism and less frequent dosing could enhance weight loss and diabetes management, potentially capturing a significant market share. Analysts project MariTide could generate $5 billion in peak annual revenue, bolstering Amgen's growth amidst competition from Eli Lilly, Novo Nordisk, and others. Despite competitive pressures and regulatory risks, MariTide's advancement into Phase 3 trials positions Amgen for mid-to-high single-digit revenue growth, making AMGN stock a "buy". Read the full article on Seeking AlphaHissedar Getirileri
| AMGN | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 6.1% | 7.5% | -2.6% |
| 1Y | 29.3% | 40.6% | 20.0% |
Getiri vs. Endüstri: AMGN geçen yıl % 40.6 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: AMGN geçen yıl % 20 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| AMGN volatility | |
|---|---|
| AMGN Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: AMGN son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: AMGN 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1980 | 31,500 | Bob Bradway | www.amgen.com |
Amgen Inc. dünya çapında insan terapötiklerini keşfeder, geliştirir, üretir ve sunar. Şirketin başlıca ürünleri arasında romatoid artrit, plak psoriasis ve psoriatik artrit tedavisi için Enbrel; plak psoriasis, psoriatik artrit ve Behçet hastalığı ile ilişkili oral ülserleri olan yetişkin hastaların tedavisi için Otezla; osteoporozlu postmenopozal kadınları tedavi etmek için Prolia; iskeletle ilgili olayları önlemek için XGEVA; miyokard enfarktüsü, inme ve koroner revaskülarizasyon risklerini azaltan Repatha bulunmaktadır; İmmün trombositopenisi olan hastaların tedavisi için Nplate; nükseden veya refrakter multipl miyelomlu hastaları tedavi etmek için KYPROLIS; normalden düşük kırmızı kan hücresi sayısı ve anemiyi tedavi etmek için Aranesp; menopoz sonrası kadınlarda osteoporoz tedavisi için EVENITY; Vahşi tip RAS metastatik kolorektal kanserli hastaları tedavi etmek için Vectibix; akut lenfoblastik lösemili hastaların tedavisi için BLINCYTO; tiroid göz hastalığını tedavi etmek için TEPEZZA; ve kronik refrakter gut tedavisi için KRYSTEXXA. Ayrıca PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA VE VECTIBIX dahil olmak üzere diğer ürünleri de pazarlamaktadır, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA VE PROCYSBI.
Amgen Inc. Temel Bilgiler Özeti
| AMGN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$190.42b |
| Kazançlar(TTM) | US$7.80b |
| Gelir(TTM) | US$37.22b |
24.8x
F/K Oranı5.2x
P/S OranıAMGN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AMGN gelir tablosu (TTM) | |
|---|---|
| Gelir | US$37.22b |
| Gelir Maliyeti | US$10.63b |
| Brüt Kâr | US$26.59b |
| Diğer Giderler | US$18.79b |
| Kazançlar | US$7.80b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 14.45 |
| Brüt Marj | 71.44% |
| Net Kâr Marjı | 20.96% |
| Borç/Özkaynak Oranı | 623.8% |
AMGN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
2.8%
Mevcut Temettü Verimi67%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/26 16:09 |
| Gün Sonu Hisse Fiyatı | 2026/06/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Amgen Inc. 61 Bu analistlerden 32, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |